Noriko Odani-Kawabata

发表

ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model

Hiroshi Nakamura, K. Nishioka, T. Matsubara, 2010, BMC musculoskeletal disorders.

Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)

M. Aihara, Naveed B K Shams, Fenghe Lu, 2019, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.

Naveed B K Shams, Noriko Odani-Kawabata, K. Yamamura, 2018, Investigative ophthalmology & visual science.

Glaucoma Pharmacologic Characterization of Omidenepag Isopropyl , a Novel Selective EP 2 Receptor Agonist , as an Ocular Hypotensive Agent

Naveed B K Shams, Noriko Odani-Kawabata, K. Yamamura, 2018 .

Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits.

Noriko Odani-Kawabata, Masatsugu Nakamura, N. Ishida, 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Ocular hypotensive effects of anti-glaucoma agents in mice.

Noriko Odani-Kawabata, Masatsugu Nakamura, N. Ishida, 2009, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study

M. Aihara, Naveed B K Shams, Fenghe Lu, 2020, Japanese Journal of Ophthalmology.

Prostanoids in the therapy of glaucoma.

H. Hara, Noriko Odani-Kawabata, N. Ishida, 2006, Cardiovascular drug reviews.

Combination effect of Bucillamine and Methotrexate on rat type II collagen-induced arthritis model

M. Sasano, H. Aono, F. Tsuji, 2007 .

Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.

Naveed B K Shams, Noriko Odani-Kawabata, R. Iwamura, 2018, Journal of medicinal chemistry.

FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma.

N. Sharif, Fenghe Lu, L. Pinchuk, 2023, Experimental eye research.

Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells

Y. Sugimoto, Naveed B K Shams, Tomoaki Inazumi, 2020, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.

M. Fuwa, C. Toris, Naveed B K Shams, 2018, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study

M. Aihara, Fenghe Lu, Noriko Odani-Kawabata, 2021, Japanese Journal of Ophthalmology.

Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

M. Aihara, Naveed B K Shams, Fenghe Lu, 2019, Journal of glaucoma.

Omidenepag Isopropyl Versus Latanoprost in Primary Open-angle Glaucoma and Ocular Hypertension: ThePhase 3 AYAME Study.

M. Aihara, Naveed B K Shams, Fenghe Lu, 2020, American journal of ophthalmology.

Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study

Y. Kuwayama, Fenghe Lu, D. Wirta, 2022, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Six-month efficacy and safety outcomes of a novel selective EP2 agonist omidenepag isopropyl: the RENGE study (Phase 3)

M. Aihara, Naveed B K Shams, Fenghe Lu, 2018 .

A Phase 3 trial comparing omidenepag isopropyl 0.002% with latanoprost 0.005% in primary open-angle glaucoma and ocular hypertension: the AYAME study

M. Aihara, Naveed B K Shams, Fenghe Lu, 2018 .

IOP lowering effect of omidenepag isopropyl in latanoprost non-/low-responder subjects with primary open-angle glaucoma or ocular hypertension: the FUJI study

M. Aihara, Naveed B K Shams, Fenghe Lu, 2018 .

Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells

M. Fuwa, Noriko Odani-Kawabata, R. Iwamura, 2023, PloS one.

Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.

M. Fuwa, Naveed B K Shams, Noriko Odani-Kawabata, 2021, Journal of Ocular Pharmacology and Therapeutics.

The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice

Naveed B K Shams, O. Katsuta, Noriko Odani-Kawabata, 2020, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)

Phillip Dinh, Fenghe Lu, A. Chabi, 2021, Journal of glaucoma.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Fenghe Lu, Noriko Odani-Kawabata, Ki Ho Park, 2024, Clinical ophthalmology.